An Overview of Eribulin Interactions
Eribulin mesylate (
Halaven™) is a prescription medication licensed to treat
breast cancer. This medication may react with certain other medications.
Some of the drugs that may lead to interactions with eribulin include but are not limited to:
- Other chemotherapy medications
- Medications that can cause a specific change in the heart rhythm known as QT prolongation (see QT-Prolonging Medications for a list of such medications).
Drug Interactions With Eribulin Explained
The following sections explain in detail the potentially negative reactions that can occur when eribulin is combined with any of the drugs listed above.
Other Chemotherapy Medications
Most chemotherapy medications have a tendency to cause similar serious side effects, such as low white blood cells, nausea, and anemia. Combining eribulin with other chemotherapy drugs might increase the risk of severe side effects. Your healthcare provider will take this into account when anticipating and treating any side effects that may occur.
QT-Prolonging Medications
In studies, eribulin was shown to potentially cause a change in heart rhythm known as QT prolongation. This is a potentially serious change that can lead to life-threatening arrhythmias. Combining eribulin with other medications that have this potential probably increases the risk. If you must combine eribulin with other QT-prolonging medications, your healthcare provider should closely monitor your heart rhythm.
HealthSavvy Sign In
|
